Reports of Biochemistry
and Molecular Biology
Wed, Feb 4, 2026
[Archive]
Vol.14 No.2 Jul
Back to the articles list |
Back to browse issues page
Razieh Zare 
, Mohammad Javad Mokhtari * , Mohammad Javad Fattahi , Nazanin Mohammadi , Bijan Khademi
, Mohammad Javad Mokhtari * , Mohammad Javad Fattahi , Nazanin Mohammadi , Bijan Khademi
Department of Biology, Zarg.C., Islamic Azad University, Zarghan, Iran.
Abstract: (29 Views)
Background: Oral squamous cell carcinoma (OSCC) represents the predominant form of cancer affecting the oral cavity, accounting for more than 90% of all oral malignancies. Despite advancements in treatment, the five-year survival rate has remains relatively unchanged, primarily due to late-stage diagnosis. This study aimed to evaluate the genetic variation in MutL homolog 1 (MLH1) (rs63749795) in patients with OSCC.
Methods: A cross-sectional case-control study was performed, including a total of 102 patients diagnosed with OSCC and 100 healthy individuals serving as controls. Genotyping of the MLH1 rs63749795 polymorphism was performed using tetra-primer amplification refractory mutation system-polymerase chain reaction (TP-ARMS-PCR) method, followed by agarose gel electrophoresis.
Results: The predominant genotype observed in both OSCC patients and healthy controls was the CT genotype, with respective frequencies of 45.1% and 55%. The least frequent genotype in both groups was TT, with frequencies of 12.7% in patients and 17% in controls. Most patients were in tumor grade 1 (70.96%) and tumor stage III (35.8%). Among the patients, 53.3% showed lymph node involvement. No statistically significant associations were observed between clinicopathological features and genotypes (P>0.05). The allele frequencies of MLH1 rs63749795 did not differ significantly between patients and controls. However, the rs63749795 polymorphism was associated with reduced OSCC susceptibility under the dominant genetic model (OR = 0.53, 95% CI = 0.29-0.96, P = 0.03 for CT+TT vs. CC genotype).
Conclusions: The MLH1 rs63749795 polymorphism may be associated with reduced susceptibility to OSCC under the dominant genetic model; however, although further studies involving larger populations are needed.
Methods: A cross-sectional case-control study was performed, including a total of 102 patients diagnosed with OSCC and 100 healthy individuals serving as controls. Genotyping of the MLH1 rs63749795 polymorphism was performed using tetra-primer amplification refractory mutation system-polymerase chain reaction (TP-ARMS-PCR) method, followed by agarose gel electrophoresis.
Results: The predominant genotype observed in both OSCC patients and healthy controls was the CT genotype, with respective frequencies of 45.1% and 55%. The least frequent genotype in both groups was TT, with frequencies of 12.7% in patients and 17% in controls. Most patients were in tumor grade 1 (70.96%) and tumor stage III (35.8%). Among the patients, 53.3% showed lymph node involvement. No statistically significant associations were observed between clinicopathological features and genotypes (P>0.05). The allele frequencies of MLH1 rs63749795 did not differ significantly between patients and controls. However, the rs63749795 polymorphism was associated with reduced OSCC susceptibility under the dominant genetic model (OR = 0.53, 95% CI = 0.29-0.96, P = 0.03 for CT+TT vs. CC genotype).
Conclusions: The MLH1 rs63749795 polymorphism may be associated with reduced susceptibility to OSCC under the dominant genetic model; however, although further studies involving larger populations are needed.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2025/06/11 | Accepted: 2025/12/25
Received: 2025/06/11 | Accepted: 2025/12/25
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
